Back to article: The emerging role of minor intron splicing in neurological disorders

FIGURE 3: Impaired minor intron splicing in SMA and ALS. Many of the molecular defects observed in patient tissues or disease modelling systems ultimately converge on affecting the spliceosome and minor intron splicing. These include both gain- and loss-of-function mechanisms in the nucleus as well as in the cytoplasm. Defects linked with SMA are indicated with a yellow rectangle, while blue rectangles mark ALS-associated defects.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.